Sitemap

Global Investor Forum Life Science in Maastricht

ILYA Pharma won the ATTD Startup grant

ILYA Pharma receives a grant from VINNOVA

PharmabioticsGlobal 2017

ILYA Pharma presents at NGM Live tomorrow May 16

Professor Mia Phillipson in the studio at the presentation of the Nobel Prize Laureates in Physiology or Medicine

ILYA Pharma wins SweLife Accelerator grant

Ilya Pharma is awarded three million euros from H2020 EU SME programme

The innovation and the MOA published by high ranking scientific journal PNAS

The CEO of Ilya Pharma ranked #20 top entrepreneur in Sweden

Ilya Pharma in the hot spot

Female entrepreneurs leading the way

SwedenBIO Award 2018

New project manager

Celebration of safety- and efficacy data from the last preclinical study

ILYA Pharma will present at the Nordic Life Science Days

ILYA Pharma is growing and recruiting

A platform for new biologics and technology innovations

Ilya Pharma raises additional Euro 3 million to take novel ATMP through to Phase II for wound care

Ilya Pharma is presenting at "INNOVATIONS IN WOUND HEALING 2018" FL 7-10 dec.

Ilya Pharma is opening a new indication and recruits a post doctoral scientist with focus on IBD

Selected top 500 globally of emerging companies in deep tech, Hello Tomorrow challenge

Evonik 2019

EIC Investor Day@Nasdaq

Advanced Wound Care Seminar Redeye in Stockholm

Hello Tomorrow Investor day

Ilya Pharma winner at Hello Tomorrow Global Challenge 2019

Ilya Pharma will present at the 29th Conference of the European Wound Management Association, Gothenburg 5-7 June

Ilya Pharma will present at Nordic Life Science Days 11-12 September, Malmö

Ilya Pharma selected to present at Biopharm America/Boston Biotech week 9-12 September

Ilya Pharma - one of the selected 30 most innovative companies, RESI2019, Boston Biotech Week

Ilya Pharma will present clinical developments at Bio Investor Forum SF 22-23 October

Ilya Pharma selected top Innovator and will present at the New England Venture Summit December 4 in Boston

Ilya Pharma will present new data and development plans for our ILP100 candidate at IBD Innovate, organised by Chrones and Colitis Foundation, NYC 4th of December

Evelina Vågesjö and the achievements of Ilya Pharma recognised by MIT Tech Review Innovators under 35

Ilya Pharma selected to present at the IMCAS Congress Innovation Shark Tank in Paris, 31st Jan 2020

Ilya Pharma will present recent clinical data at Advanced Therapies Congress & Expo 2020 in London March 31

Ilya Pharma will present developments at SwissNordicBio 6th of February 2020 in Zuric

Ilya Pharma selected to present at the BIO CEO Investor forum in NYC 10-11th of February.

Ilya Pharma’s ILP100 Phase I wound care therapy trial progresses swiftly to multiple dosing

COVID-19

Operational Report Q1 2020

Resuming recruitment to the ongoing clinical trial - final cohorts

Ilya Pharma awarded Euros 5.3 million from EIC Accelerator to fast track Phase II study of first-in-class ILPI100 advanced therapy for wound treatment in people with diabetes

Ilya Pharma awarded risk-shared funding by EIT Health

Operational Report Q2 2020

Meet Margareth Jorvid - leading innovations to products

Some thoughts from the CEO

Meet Ingemar Kihlstörm - facilitating the next stage of growth

Operational Report Q3 2020

FDA open to new endpoints for patients with difficult wounds

Latest clinical developments and next raise to be presented at EIC Investor Day 2.0 17-18 December

Ilya Pharma will present at the Swiss Nordic Bio 10-11 February 2021

Meet Stefan Roos co-founder and innovator for multiple patents of commercial strains of lactic acid bacteria

Ilya Pharma extends research collaboration with Uppsala University

Ilya Pharma presented at the Redeye unlisted event December 2

Ilya Pharma announces positive results from Phase I trial of lead candidate ILP100 and rapid move to Phase II

Ilya Pharma approved for funding by the European Innovation Council Equity Fund for high-impact innovation

Ilya Pharma awarded European patent covering engineered Lactobacillus reuteri strains for use in cutaneous wound therapy

Ilya Pharma will present at Bio€quity Europe Digital 17-19 May

Ilya Pharma will present at Nordic Life Science Invest Digital 19 April 2021

Ilya Pharma will present recent clinical data and planned studies for ILP100 Topical and Oral at Pharmabiotics 28-29 April 2021

Pfizer veteran Sylvia McBrinn joins Board while Oskar Lund becomes CFO as Ilya Pharma strengthens senior management - top news shared by FirstWord Pharma

Ilya Pharma Receives Approval from Swedish Regulators to Initiate Phase II Clinical Study of ILP100 Gene Therapy to Treat Difficult Wounds Patients with Diabetes

Open position - Senior Clinical Trials Manager for phase II/III study

Ilya Pharma will present at Microbiome Movement 3-5 August

Ilya Pharma selected to present at BioFuture 4-8 October in NYC at Cure in the session of "Breakthrough Therapies: Brought to you by Game Changing Technologies!

Ilya Pharma will be participating at the Swedish American Life Science Summit 2021 October 20-22 and is nominated to the Rising Star Award

Ilya Pharma will be participating at Jefferies London Healthcare Conference 16-19 November

Professor Mia Phillipson will present Nature Conferences Innovative Tissue Therapies from Bench to Bedside 16-18 November

Ilya Pharma shares latest developments of ILP100-Oral at virtual conference 7th of December showcasing innovations in gut therapeutics

Ilya Pharma will present clinical and corporate updates at Biotech Showcase 10-13 January at JPM Week 2022

Ilya Pharma invited to attend the 40th JP Morgan Health Care Conference 10-13 January, 2022

Open position as CMC project manager

Ilya Pharma presenting at Hybrid event BIO CEO Investor conference in NYC 14-17 February 2022

Ilya Pharma participating in Texas Life Science Forum, Houston 23-24 February 2022

Scientific abstract of ILP100-Oral in two colitis models selected for poster at Experimental Biology Philadelphia April 4 2022

8.5 MEUR to advance our three programs

Ilya Pharma makes strategic investment in bioanalytical company

FDA clearance of IND for first-in-class ILP100-Topical immunotherapy treatment of surgical wounds in patients with prediabetes, diabetes and obesity

Ilya Pharma present at BIO San Diego 13-16 June

Labiotech.eu reports on Ilya Pharmas latest new patents covering major markets

Ilya Pharma presents poster at US Military Health System Research Symposium in Florida September 12

Ilya Pharma appoints Leo Groenewegen as CEO of recent acquisition Nordic Bioanalysis

Ilya Pharma at Nordic Life Science Days Malmö 28-29 September

Ilya Pharma will present company updates at BioFuture hosted live in NYC 7-8 November and virtually 14-16 November

Ilya Pharma will attend Jefferies Health Care Conference in London 15-16 Nov

Ilya Pharma is present at the 2023 JPM week in San Francisco 9-13 January

Ilya Pharma have had a successful preIND meeting with the FDA related to the development of ILP100-Oral

Ilya Pharma will participate at AMWC 2023 - 21st Aesthetic & Anti-Aging Medicine World Congress

Abstract selected for poster presentation at International Society for Cell- and Gene Therapy 2023 London May 2023

Presentation of results from the SITU-SAFE study at EWMA 2023 in Milan on Friday May 5th

The value of regulatory interactions developing a new modality in gene therapy- presentation at ISCT Paris May 31 - June 3

Presentation of science and an update on the ILP100-development at Broad Institute by MIT and Harvard by Professor Mia Phillipson, May 19th in Boston

Keynote presentation at the National Molecular Medicine Fellows by CEO Evelina Vågesjö

NOTICE OF ANNUAL GENERAL MEETING IN ILYA PHARMA AB (PUBL) June 26

First RCT with ILP100 published in Lancet Discovery Sciences eClinicalMedicine

Dr Andreas Fasth will present the planned SITU-SURGERY trial at the US Military partnering conference MHSRS in Kissimmee, FL on August 16

Dr Evelina Vagesjö will give clinical update at The European Chemokine and Cell Migration Conference (ECMC) 2023 August 21st, Leuven, BE

Nailing of a Thesis - "Live Biotherapeutics - Importance of formulation and lyophilization parameters and an example of a clinical application"

Ilya Pharma presenting at ECMC2023 Leuven September 20-22, 2023

Ilya Pharma is participating in the Jefferies Healthcare Conference in London, Nov 14-16

Nailing of a Doctoral Thesis

Seminar at SciLifeLabs by Professor Neil Forbes - pioneer of genetically modified bacteria for treatment of solid tumors

Ilya Pharma is attending the 42nd Annual J.P. Morgan Healthcare Conference in SF 8-11 Jan

Ilya Pharma presents at Uppsala University Pharmaceutical Science Day 1st February in Uppsala

Ilya Pharma receives funding by HORIZON Marie Sklodowska-Curie Doctoral Network B-ACTIVE

Ilya Pharma presents at Biologics World Nordic in Copenhagen March 6-7

Ilya Pharma gives an update at Pharmabiotics in Lille, France March 13-15

One PhD Position in chemokine immunobiology - HORIZON-MSCA-2022-DN Doctoral Network “B-ACTIVE”

Presentation of new data of antimicrobial effects on multi-drug resistant bacterial infections from Ukraine war victims

Open position part-time accounting assistant

New publication in American Journal of Physiology Gastrointestinal and Liver on the MOA and PoC for ILP100-Oral in multiple models of colitis

Ilya Pharma presents clinical update at 9th Microbiome Movement Drug Development Summit, Boston 10-12 July

Ilya Pharma will present Poster with AMR data for ILP100 at US military medical partnering conference MHSRS August 26-29 August, Kissimmee, FL

Open position: Translational and clinical scientist and project manager

Open position: CFO